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Background/aim: Pericytes are mesenchymal cells surrounding capillary vessels and are known to play an essential role in tumor
angiogenesis. Chondroitin sulfate proteoglycan 4 (CSPG4) is a cell surface proteoglycan and its release from pericytes and vascular
smooth muscle cells is very important in tumor angiogenesis. Bevacizumab, which is a monoclonal antibody frequently used in the
treatment of metastatic colorectal cancer, binds to the ligand of vascular endothelial growth factor A (VEGFA) and inhibits tumor
angiogenesis. However, no reliable biomarker for predicting patients that will show a good response to this therapy has been established
yet.
In this study, we aimed to identify the significance of the presence of pericyte and VEGFA and CSPG4 expressions on the efficacy of
Bevacizumab.
Materials and methods: Fifty patients with metastatic or recurrent colorectal cancer who had been treated with Bevacizumab combined
chemotherapy treatment were included in the study. The expressions of VEGFA and CSPG4 genes and also human β-actin as the
reference gene were examined using the quantitative real-time polymerase chain reaction method in the formalin-fixed paraffinembedded tumor tissues. For determining vascular and pericyte density in tumor tissue, immunohistochemical analysis was performed
with CD31, alpha-smooth muscle actin, and CD34 antibodies.
Results: CSPG4 positive group had better objective response rate, as well as longer progression-free and overall survival than CSPG4
negative ones. Progression-free survival was significantly longer in VEGFA low group and CD31 low group. No significant correlation
was found between CD34 positivity, SMA positivity, and progression-free and overall survival.
Conclusion: Our results suggested that bevacizumab may be more effective in patients having less vascular density in the tumor tissue.
But further studies are needed to support this finding.
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1. Introduction
Colorectal cancer (CRC) is a significant cause of morbidity
and mortality throughout the world [1]. It is the second
most common cancer in women and the third most
common cancer in men [2]. The median survival time of
patients with advanced CRC is around 2 years [3].
In recent years, the addition of chemotherapy to
targeted therapies has resulted in some improvement
in survival outcomes. Among these drugs, the most
commonly used one is bevacizumab, which binds to the
ligand of vascular endothelial growth factor A (VEGFA).
VEGFA is an essential ligand in angiogenesis. VEGFA
enhances capillary permeability and endothelial cell
proliferation via VEGFR-2 tyrosine kinase receptors

expressed in endothelial cells [4].
Bevacizumab, in combination with chemotherapy,
increases the survival rate in patients with metastatic
colorectal cancer [5,6]. However, it is useful in only 30%–
40% of the patients. Any parameter or marker, which can
be used for selecting the patient group that will benefit
from bevacizumab therapy, has not been found yet.
Pericytes are mesenchymal cells surrounding capillary
vessels and are in close contact with endothelial cells
[7]. Pericytes envelop and support endothelial cells and
promote vessel growth and maturation. Chondroitin
sulfate proteoglycan 4 (CSPG4), which is a member of
transmembrane chondroitin sulfate proteoglycans family,
is released from pericytes. CSPG4 guides endothelial tip
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cells to lead to the tubular structure during the angiogenesis
in the direction of hypoxic tumor [8]. Therefore, pericytes
play an essential role in initiating vascular destabilization
and the formation and migration of endothelial end cells in
the early stage of tumor angiogenesis. The role of pericytes
in the formation of new vessels in tumors has been shown
in various studies and the low pericytic area was found to
be associated with poor prognosis [9, 10].
With these in the background, we aimed to investigate
the effect of the presence of vessel and pericyte density, and
VEGFA and CSPG4 expressions in the tumor tissue, on
the efficacy of the bevacizumab in metastatic or recurrent
colorectal cancer patients.
2. Materials and methods
2.1. Patients and study design
After the Clinical Research Ethics Committee of Ankara
University had approved the study protocol (approval
no: 19-963-16), 50 patients with metastatic or recurrent
colorectal cancer who had been treated with bevacizumab
for at least 2 months in addition to the routine chemotherapy
protocol were included. Following the approval, the
formalin-fixed paraffin-embedded tumor tissue samples
of the patients were used. VEGFA and CSPG4 gene
expressions were determined with quantitative real-time
PCR, and for determining vascular and pericyte density,
immunohistochemical analysis was employed.
2.2. Quantitative real-time PCR (qPCR)
Forward and reverse primers and FAM TAMRA stained
probes for quantitative real-time PCR (qPCR) analysis of
VEGFA and CSPG4 genes were designed with Primer3
web (version 4.0.0) program [11]. Human β-actin (HBA)
gene was used as the reference gene for the analysis. Primer
BLAST and NCBI BLAST were used to check whether
the primers and probes designed are specific to the target
gene and control the level of homodimer and heterodimer
binding [12,13]. Moreover, IDT OligoAnalyzer 3.1 and
PerlPrimer software were used [14,15]. The primer and
probe sequences used in qPCR analyses are shown in Table
1.
RNA was extracted from paraffin-embedded blocks
of the patients using a commercial kit (RNeasy FFPE Kit;
QIAGEN, Hilden, Germany), samples with RNA purity
between 2.1 ≥ λ260 and λ280 ≥ 1.8 were used in the study

and RNA quality was evaluated through visualization of
the 28S:18S ribosomal RNA ratio on a 2% agarose gel.
Complementary DNAs (cDNAs) were produced from 1 μg
of RNA of each sample using a commercial kit (FIREScript
cDNA Synthesis KIT; Solis Biodyne, Estonia) according to
the manufacturer’s instructions.
qPCR analysis was performed on CFX96 RealTime
System (Biorad C1000 Thermal Cycler, California, USA).
Using the qPCR mix, the PCR reaction mixture consisted
of 3 μL of cDNA including primers and FAM-TAMRA
stained TaqMan probes 0.3 µL (10 pmol/μL), 2 µL of
qPCR Mix (Solis Biodyne 5x Hot FirePol Probe Mix Plus
(No Rox), Estonia), and 4.1 DNAse-RNAse free water in
a final volume of 10 μL per reaction. Cycling conditions
were 95 °C for 15 min, followed by 40 cycles at 95 °C for
20 s and 60 °C for 1 min, and then 37 °C for 10 min. The
specificity of the qPCR products was confirmed by melting
curve analysis and 2% agarose gel electrophoresis (Figure
1). All samples were analyzed in a triple in qPCR assay. The
relative quantification of the expression of each gene was
calculated by the 2-Δ(Δct) method [16].
2.3. Immunohistochemical studies
Hematoxylin & eosin-stained slides (Figure 2a) were
reevaluated and the appropriate tumor blocks for the
immunohistochemical study were selected. Fourmicrometer thick sections were taken and stained with antiCD31, anti-alpha-SMA, and anti-CD34 antibodies on the
Ultraview Universal DAB Detection Kit (Ventana, Cat. No.
05269806001) on a fully-automated immunohistochemical
staining device (Ventana, BenchMark ULTRA). AntiCD31 (Santa Cruz, sc-376764), anti-alpha-SMA (Santa
Cruz, sc-53142), and anti-CD34 (Santa Cruz, sc-74499)
primary antibodies were used. When evaluating the results
of immunohistochemistry, staining of the necrotic areas (if
any) and edge regions of the tissues were not taken into
consideration considering the possibility of false positivity.
The vessels were stained with anti-CD31, anti-CD34, and
anti-alpha-SMA immunohistochemically, and the sections
were examined at 20× and 100× magnification, and the
regions containing the most microvascular structures
were determined. The vessels in these regions were
counted at 20× magnification and the vascular density was
determined (Figures 2b–2d). Analysis was made by using
the hotspot Weidner’s method [17].

Table 1. Designed primer and probe sequences.
Gene

Forward primer

Reverse primer

Probe

HBA

5’-CCTGGAGAAGAGCTACGAG-3’

5’-AAGGTAGTTTCGTGGATGCC-3’

5’-CCAGCCTTCCTTCCTGGGCA-3’

VEGFA

5′-TACTGCCATCCAATCGAGAC-3′

5′-GAGGAGTCCAACATCACCAT-3′

5′- ATGCGGGGGCTGCTGCAATGA-3′

CSPG4

5’-TGACCCTGACTATGTTGGCC-3′

5’-GCAGGTCTATGTCGGTCAGA-3′

5’-CCGCGGCTTCCTTCTTCGGTGA-3′
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Figure 1. Images of some PCR amplified samples for 2% gel for HBA, VEGF, and CSPG4 genes. HBA
product size: 134 bp; VEGFA product size: 161 bp; and CSPG4 product size: 102 bp.

Figure 2. Microscopic pictures of colon adenocarcinoma (a) Tumor
development with atypical epithelial cells forming glandular structures,
Hematoxylin and eosin stain, 200×, (b) anti-CD31 immunohistochemistry,
200×, (c) anti-CD34 immunohistochemistry, 200×, and (d) anti-alpha SMA
immunohistochemistry, 200×. Black arrows indicate the vascular structures.

2.4. Statistical analysis

SPSS 10.0 software was used for statistical analysis. Variables
were used as mean ± standard deviation and percentage and
frequency values. In addition, homogeneity of variances from
prerequisites of parametric tests was checked by the Levene test.
The test of normality was examined by the Shapiro–Wilk test.
For the comparison of two groups, Student’s t-test and Mann–
Whitney U test were used.

For CD31, CD34, and anti-alpha SMA, cut-off values
were calculated by ROC curve analysis. In the Youden

index, the maximum value according to the formula
maximum = sensitivity + specificity-1 was taken as cut-off
values. Survival analysis was evaluated with the Kaplan–
Meier method and the comparison of survival time
between the categories of variables was evaluated by the
log-rank Mantel–Cox test. In this study, the Cox regression
analysis was used to reveal the model of the relationship
between independent variables and dependent variables
(survival status). The relationships between categorical
variables were analyzed with Fisher’s exact test and χ² tests.
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3. Results
Sex, age, primary tumor localization, disease status,
metastasis site, KRAS mutation status, CEA level at
diagnosis, Bevacizumab setting, and the chemotherapy
schemes administered with bevacizumab are shown in
Table 2. Female/male ratio was 0.47. The median age of
the patients was 59 years ranging between 34 and 76. Left
colon was more frequently seen as the primary tumor site

(70%). Sixty-eight percent of the patients had metastasis
and 32% had recurrence. Liver was the most frequent
metastasis site (80%), followed by lung (28%), lymph
node (28%), and peritoneum-omentum-mesentery (18%).
Forty-six percent of the tumors showed KRAS mutation,
40% of the tumors was KRAS wild type, and KRAS status
was not known in 14% of the tumors. Serum CEA levels
were high in 58% of the patients. Bevacizumab was used

Table 2. Patient characteristics.
Parameter
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Sex
Female
Male

n (%)
16 (32%)
34 (68%)

Age
Median (range)
<50 n (%)
>50 n (%)

59 (34–76)
13 (26%)
37 (74%)

Tumor localization
Right colon
Left colon

n (%)
15 (30%)
35 (70%)

Disease status
Metastatic
Recurrence

n (%)
34 (68%)
16 (32%)

Metastasis site
Liver
Lung
Lymph node
Peritoneum-omentum-mesentery

n (%)
40 (80%)
14 (28%)
14 (28%)
9 (18%)

KRAS mutation status
Mutant
Wild type
Unknown

n (%)
23 (46%)
20 (40%)
7 (14%)

CEA level at diagnosis
High
Normal

n (%)
29 (58%)
21 (42%)

Bevacizumab setting
First line
Second line
Third line
Fourth line

n (%)
39 (78%)
5 (10%)
4 (8%)
2 (4%)

Chemotherapy
Irinotecan/5-FU-based
Oxaliplatin/5-FU-based
Fluoropyrimidine

n (%)
43 (86%)
4 (8%)
3 (6%)
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in the first-line therapy in 78% of the patients, second-line
in 10% of the patients, third-line in 8% of the patients,
and fourth-line in 4% of the patients. Chemotherapy
modalities administered with bevacizumab were as follows;
irinotecan-based in 86% of the patients, oxaliplatin-based
in 8% of the patients, and fluoropyrimidine in 6% of the
patients.
The treatment outcomes of the patients are listed in
Table 3. The median number of bevacizumab cycles was 4,
ranging between 2 and 18. The objective response rate was
31.1% with a median duration of 5.6 months. The median
progression-free survival (PFS) was 8.72 ± 0.8 months (95%
confidence interval [CI]: 7.1–10.3), and the median overall
survival (OS) was 17.0 ± 2.8 months (95% CI: 11.4 – 12.6).
Quantitative real-time PCR analysis revealed that
20 of the patients (40%) showed VEGFA low expression
(VEGFA/HBA<0.5), while 30 of the patients (60%)
expressed high VEGFA (VEGFA/HBA>0.5). In addition,
7 of the patients (14%) expressed CSPG4. The objective
response rates according to the quantity of VEGFA and
the presence of CSPG4 are shown in Table 4. Objective
response rates were similar in VEGFA low (39.1%) and
VEGFA high (22.7%) (p = 0.235) groups. Besides, there
was no statistically significant difference between CSPG4
positive (36.6%) and CSPG4 negative (0%) groups for the
objective response rates (p = 0.054).
Progression-free and overall survival of the patients
was analyzed with the Kaplan–Meier method according to

the expression of HBA, VEGFA, and CSPG4 genes. The
progression-free survival of the VEGFA high group was less
than that of the VEGFA low group (p = 0.0066) (Figure 3).
There was no statistically significant difference in overall
survival between VEGFA high group and VEGFA low
group (p = 0.3036). For CSPG4, the progression-free and
overall survival of the CSPG4 positive group seems to be
better than the CSPG4 negative group without statistical
significance (23.9 ± 18.9 vs 15.4 ± 2.8 months; p = 0.4177,
p = 0.5038, respectively).
When the results obtained by immunohistochemical
staining of CD31, CD34, and alpha-SMA antibodies were
evaluated, the median value for vascular density was 48 for
CD31, 19.5 for CD34, and 6 for alpha-SMA. According to
the Youden index, the cut-off values for vascular density
were 39 for CD31, 12.5 for CD34, and 2.5 for alpha-SMA.
There was a significant negative correlation between
CSPG4 expression and CD31 (r: –0.3428, p: 0.012),
whereas a negative correlation was found between CD34
and alpha-SMA expression. There was a weak correlation
between VEGF expression and CD34 (r: 0.251, p: 0.096)
and SMA (r: 0.273, p: 0.069), but not with CD31. Both
progression-free survival (p = 0.042) and overall survival
(p = 0.033) were found to be better in those with low CD31
expression (Figure 4). There was no statistically significant
difference between CD34 high and CD34 low groups in
terms of progression-free and overall survival (p = 0.8508,
p = 0.2049, respectively).

Table 3. Treatment outcomes.
Parameter
Bevacizumab cycles
Median (range)

4 (2–18)

Objective response rate

31.1%

Response duration, months
Median ± SEM
95% CI

5.6 ± 0.4
4.7–6.5

Progression-free survival, months
Median ± SEM
%95 CI

8.72 ± 0.8
7.1 – 10.3

Overall survival, months
Median ± SEM
95% CI

17.0 ± 2.8
11.4–12.6

SEM: Standard error of mean, CI: Confidence interval
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Table 4. Objective Response Rate for VEGFA and CSPG4.
Objective response rate

p-value

VEGFA low (VEGFA/HBA < 0.5)
VEGFA high (VEGFA/HBA > 0.5)

39.1%
22.7%

0.235

CSPG4-positive
CSPG4-negative

36.6%
0%

0.054

Figure 3. Progression-free survival (PFS) curves according to the
quantity of VEGF in primary tumor tissue. PFS was significantly
longer in the VEGFA low group (p = 0.0066).

Figure 4. Overall survival (OS) according to the quantity of
CD31. The OS for CD31 low group was significantly longer (p
= 0.033).

4. Discussion
Bevacizumab, in combination with chemotherapy,
increases the survival rate significantly in patients
with metastatic colorectal cancer [5,6]. Although the
antiangiogenic drugs improve survival in clinical trials, a
large number of patients up to 60% do not benefit from
the treatment. More than half of the patients experience
treatment toxicity without getting any useful result at all.
When treatment costs and vascular complications are
considered, it is vital to identify patients who may benefit
from antiangiogenic therapies. Although biomarker
studies to predict the efficacy of antiangiogenic treatment
is continuing, there have been no reliable markers that can
be used in the clinic practice yet.
VEGF stimulates the division of endothelial cells in
resting tumors and allows them to form new blood vessels
[18]. Pericytes and vascular smooth muscle cells have been
reported as the sources of VEGF for endothelial cells [19].
Similarly, CSPG4 expression, which is mainly processed by
pericytes, is also a very important step in angiogenesis. As
a whole, pericyte maturation is an important step in the
process of tumor angiogenesis and may provide biomarkers

predictive for bevacizumab treatment and targets for
drug development [8]. For this reason, it is important to
determine the relationship between endothelial cells and
pericytes surrounding the tumor vessels and vascular
smooth muscle cells.
In the current study, we analyzed the expression of HBA,
VEGFA, and CSPG4 genes, and meanwhile evaluated the
vascular and pericyte density with immunohistochemical
analysis of 50 colorectal patients’ tumor tissue. Although
the number of patients in our study was small and
the treatment groups were heterogeneous, there were
no significant differences in terms of the treatment in
metastatic colon cancer.
No statistically significant difference was found
for VEGFA expression for objective response rate and
overall survival time, but progression-free survival was
significantly longer in the low VEGF expression group,
pointing that the quantity of VEGF expression could be
used to assume prognosis.
A few clinical studies in the literature indicated that
low pericyte density was more associated with poor
prognosis [10] and decreased pericytes in the tumor tissue
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have been reported to support increased rate of metastasis
[20]. In a subsequent study, CD31 and alpha-SMA
antibodies were stained in metastatic CRC patients with
the immunohistochemical method. They have suggested
that perivascular cells could be a predictive marker in the
treatment of bevacizumab. [21].
In our study we evaluated the CSPG4 expressions for
having an idea of the pericytic density in the tumor tissue.
The objective response rate was better in CSPG4 positive
group, as well as progression-free, and overall survival
times without statistical significance, remarking the need
of larger series to clarify or exclude these results.
There was no correlation between CD34 and SMA
positivity and progression-free and overall survivals.
Both progression-free and overall survival were found
to be better in the group with low CD31, indicating that
immunohistochemical evaluation of CD31 may be useful in
determining the efficacy of treatment in patients receiving

bevacizumab.In conclusion, our results suggested that
bevacizumab may be more effective in patients with less
vascular density. However, further studies are needed to
evaluate the emerging role of pericytes on the efficacy of
bevacizumab.
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